Results 21 to 30 of about 197,499 (175)

Corrigendum: Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogues [PDF]

Frontiers in Endocrinology, 2021
Kevin C. J. Yuen, Bradley S. Miller, Cesar L. Boguszewski, Andrew R. Hoffman   +3 more
doaj   +2 more sources

Preclinical Investigations of a Novel PEGylated Long-Acting Human Growth Hormone

Drug Design, Development and Therapy
Jun Wang,1,2 He Wang,1,2 Rong Wang,1,2 Yu Zhuang,1,2 Chenyang Jiang,1,2 Baixue Zhao,1,2 Zhen Xu,1,2 Bruce Yong Ma1,2 1Zonhon Biopharma Institute, Inc., Changzhou, Jiangsu, People’s Republic of China; 2Jiangsu Engineering Research Center for Precision ...
Wang J, Wang H, Wang R, Zhuang Y, Jiang C, Zhao B, Xu Z, Ma BY   +7 more
doaj   +3 more sources

Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation [PDF]

Frontiers in Endocrinology, 2023
Martin Bidlingmaier, Beverly M.K. Biller, David Clemmons, Jens Otto L. Jørgensen, Hiroshi Nishioka, Yutaka Takahashi, Yutaka Takahashi   +6 more
doaj   +2 more sources

KBG Syndrome: A Case Report and Longitudinal Assessment of Long‐Acting Recombinant Human Growth Hormone Therapy [PDF]

Clinical Case Reports
This case analysis examines the clinical data, molecular genetic testing results, and 20‐month clinical data of long‐acting recombinant human growth hormone (rhGH) treatment in a child with KBG syndrome (KBGS). The child exhibited a c.1591delG frameshift
Hui Nan, Pu Zhang, Jing Qian
doaj   +2 more sources

Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency [PDF]

Annals of Pediatric Endocrinology & Metabolism
Long-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric GH deficiency, offering an alternative to daily recombinant human GH (rhGH) therapy.
Chiara Rodaro, Gianluca Tamaro, Elena Faleschini, Gianluca Tornese   +3 more
doaj   +4 more sources

Retraction: Effect of weekly long-acting growth hormone replacement therapy compared to daily growth hormone on children with short stature: a meta-analysis [PDF]

Frontiers in Endocrinology, 2023
Frontiers Editorial Office
doaj   +2 more sources

Lugol’s solution for preoperative management of a TSH/GH-secreting pituitary adenoma with suboptimal response to octreotide: a case report [PDF]

Frontiers in Endocrinology
BackgroundThyroid-stimulating hormone pituitary adenomas (TSHomas) are a rare cause of central hyperthyroidism, characterized by abnormally high TSH levels, and typically respond to somatostatin analogue (SSA).
Guiliang Peng, Xiaotian Lei, Weiling Leng, Feng Wu, Laiping Xie, Min Long, Liu Chen   +6 more
doaj   +2 more sources

Long-Acting Growth Hormone Preparations in the Treatment of Children. [PDF]

Pediatr Endocrinol Rev, 2018
Lal RA, Hoffman AR.
europepmc   +2 more sources

Long-Acting Growth Hormone Preparations and Their Use in Children with Growth Hormone Deficiency [PDF]

Hormone Research in Paediatrics, 2022
<b><i>Background:</i></b> Daily recombinant human growth hormone (rhGH) is approved and marketed worldwide to treat children and adults with GH deficiency and other conditions. Efficacy of rhGH therapy is influenced by several variables.
Pampanini, Valentina, Deodati, Annalisa, Inzaghi, Elena, Cianfarani, Stefano   +3 more
openaire   +3 more sources

Long-Acting Growth Hormone [PDF]

Pediatric Drugs, 2013
Human growth hormone (GH) is a 22 kDa protein synthesized and secreted in the anterior pituitary gland. GH synthesis and release is induced by hypothalamic GHreleasing hormone (GHRH) and ghrelin and attenuated by somatostatin and negative feedback by insulin-like growth factor (IGF)-I [1].
Höybye, Charlotte, Christiansen, Jens Sandahl   +1 more
openaire   +3 more sources